Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - April 2019

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Testosterone (Testavan®) has been accepted for restricted use as testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. The restriction limits use to patients requiring a transdermal delivery system and it is noted that this product is bioequivalent to another testosterone transdermal preparation and costs less.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - April 2019' on Email Share 'SMC Update - April 2019' on Delicious Share 'SMC Update - April 2019' on Digg Share 'SMC Update - April 2019' on Facebook Share 'SMC Update - April 2019' on reddit Share 'SMC Update - April 2019' on StumbleUpon Share 'SMC Update - April 2019' on Twitter

atomic-wealth

No Comments to “SMC Update - April 2019”

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer